Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

Heart disease is one of the leading causes of death worldwide, and while lifestyle choices like diet, exercise, and smoking ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Familial hypercholesterolemia results from gene mutations approximately halving ... decreased transintestinal cholesterol excretion. PCSK9, which mediates post-translational destruction of LDL ...

The company has launched a competition to offer grants of up to $100,000 to multiple projects that can uncover "new insights about the role of the PCSK9 protein/gene in health and disease", with a ...

At the moment, there is an LNP-based CRISPR-Cas9 candidate treatment for people with heterozygous familial hypercholesterolemia in clinical trials, which targets the PCSK9 gene in the liver.

Precision is also using its ARCUS platform to develop a treatment to edit PCSK9, a gene that regulates the levels of low-density lipoprotein (LDL) cholesterol. In preclinical studies, and three ...

It is part of a new form of medicine called gene-silencing. Inclisiran does not modify our DNA, but it controls the instructions the body gets. It does this by "silencing" the PCSK9 gene ...